There Are Only 3 Ways To Increase Your IGF-1 (How To Pick The Right One)

Your liver is the factory that converts growth hormone into IGF-1, and IGF-1 is the molecule that actually does most of the work people associate with growth hormone, including tissue repair, fat mobilization, and muscle protein synthesis. Growth hormone goes up, the liver produces IGF-1, and that IGF-1 circulates and binds to receptors throughout the body. That is the chain. Every compound in this space is just a different way of pulling that same lever.

The question is where in the chain you intervene, and that decision changes everything about how your body responds.

The first place you can intervene is at the very top, in the brain. This is what GHRH analogs do. Tesamorelin, CJC-1295, and Sermorelin are all synthetic versions of something called growth hormone-releasing hormone, which is the signal your hypothalamus naturally sends to your pituitary to trigger a pulse of growth hormone. When you inject one of these peptides, you are mimicking that natural signal and telling the pituitary to release more of what it already makes.

The pituitary responds, growth hormone rises, and the liver converts that growth hormone into IGF-1. So far this looks like the most direct route to higher IGF-1, but there is a ceiling built into this system.

When IGF-1 climbs, the body detects this and releases something called somatostatin, which is essentially the brake signal in the growth hormone axis. Somatostatin suppresses pituitary output, and growth hormone falls back down. Your IGF-1 cannot climb past what your own regulatory system permits because the feedback loop is still fully intact and actively working against you. The gas pedal works, but the brake is also working.

This is not a flaw. For most people, the goal is not to push IGF-1 as high as pharmacology will allow. The goal is to restore levels that have declined with age or metabolic stress back toward the upper range of what is physiologically normal. GHRH analogs do exactly that, and they do it while preserving the pulsatile rhythm of growth hormone secretion, which matters because continuous exposure to growth hormone is not how your body is designed to use it.

The second place you can intervene is at the growth hormone level itself. This is exogenous recombinant HGH, and the mechanism shifts in an important way. When you inject growth hormone directly, you bypass the pituitary entirely. The signal is no longer coming from inside the feedback loop. It is coming from outside it.

This is where the ceiling breaks. Research published in the Journal of Clinical Investigation found that exogenous growth hormone suppresses the pituitary's response to endogenous GHRH within about 30 minutes of injection, and a follow-up study confirmed that even low-dose exogenous 22K growth hormone is enough to suppress pituitary GH secretion in normal men, with 20K GH showing similar suppressive effects at comparable doses. Your pituitary goes quiet because the body sees circulating growth hormone and concludes it does not need to make more.

But the IGF-1 keeps rising. Because the liver does not know or care whether the growth hormone arriving is endogenous or injected. It just converts it. And without the pituitary-level brake doing its job, IGF-1 can climb above what your body would ever produce on its own.

This is the tradeoff. The ceiling is gone, but so is the regulatory architecture that protects you. This is why regular bloodwork is not optional here. IGF-1 above roughly 300 ng/mL starts entering territory associated with risks that are not worth taking lightly, and because the suppression of endogenous GH is real and measurable, running GHRH analogs alongside exogenous HGH is not additive. You are paying for a signal the pituitary is no longer listening to.

The third intervention point skips the entire growth hormone axis. IGF-1 LR3 is a modified form of IGF-1 that you inject directly. There is no pituitary step, no liver conversion step, no waiting. The IGF-1 is already there. LR3 refers to a structural modification that extends the half-life and reduces binding to IGF-1 binding proteins, which means more of the molecule stays free and active in circulation longer than natural IGF-1 would.

Research from the Journal of Clinical Endocrinology and Metabolism found that exogenous IGF-1 itself feeds back on the pituitary and the hypothalamus to suppress growth hormone secretion, meaning injecting IGF-1 directly has the same suppressive effect on your own GH output as injecting GH does, just from a different point in the chain.

The reason this has to be cycled at six to eight weeks is receptor desensitization. IGF-1 receptors, when exposed to sustained supraphysiologic IGF-1, downregulate their own sensitivity. The signal stops being read as clearly even though the molecule is still present. Continuing past that window means you are absorbing cost and risk without proportional benefit.

Now, there is a persistent belief that Tesamorelin is uniquely effective for visceral fat in a way that other growth hormone compounds are not. What is true is that the clinical trials on Tesamorelin specifically measured visceral adipose tissue, and those trials, including the 2007 NEJM study by Falutz and colleagues, showed reductions in visceral fat area of approximately 15% over 26 weeks. That is real and it is meaningful. But the mechanism is not unique to Tesamorelin. Growth hormone drives fat mobilization through a process called GH-mediated lipolysis, and visceral fat tissue has a higher density of growth hormone receptors than subcutaneous fat does. So regardless of whether growth hormone is elevated by Tesamorelin, Sermorelin, or pharmaceutical HGH, the tissue it mobilizes most readily is visceral fat. The trials measured Tesamorelin because that was the compound under investigation, not because it has exclusive access to visceral depots.

Johannsson and colleagues demonstrated in 1997 that direct growth hormone treatment in abdominally obese men reduced visceral fat mass, improved lipid metabolism, and lowered diastolic blood pressure, using pharmaceutical HGH, not a GHRH analog, and arriving at the same target tissue through the same mechanism.

The lipolytic effect also requires a calorie deficit to translate into meaningful fat loss. Growth hormone mobilizes free fatty acids from adipose tissue, but if caloric intake is sufficient to reesterify or oxidize those fatty acids back without a net energy deficit, the mobilization does not produce loss. It produces cycling. This is not a caveat. It is the mechanism.

So the three categories are not ranked by quality. They are tools for different positions in the chain, and the right one depends entirely on whether you need to work within your body's feedback architecture or outside it, and for how long.

The deeper point is that the feedback system itself is not a limitation to be circumvented by default. It exists because your body has to protect the tissues that IGF-1 acts on from chronic overstimulation. Every strategy that bypasses more of it gives you more control over the output and removes more of the protection. That is not an argument against any of these compounds. It is the argument for knowing exactly which one you are reaching for and why.

---

References

1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359-70. DOI: 10.1056/NEJMoa072375
2. Stanley TL, Grinspoon SK. (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 25(2):59-65. DOI: 10.1016/j.ghir.2014.12.005
3. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. DOI: 10.1210/er.2008-0027
4. Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J Clin Endocrinol Metab 85(2):601-6. DOI: 10.1210/jcem.85.2.6377
5. Rosenthal SM, Hulse JA, Kaplan SL, Grumbach MM. (1986). Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men. J Clin Invest 77(1):176-83. DOI: 10.1172/JCI112273
6. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO. (1998). Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I: evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83(8):2836-42. DOI: 10.1210/jcem.83.8.5040
7. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82(3):727-34. DOI: 10.1210/jcem.82.3.3809

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness